What is Deep Genomics?
Deep Genomics operates at the intersection of artificial intelligence and molecular biology, focusing on the development of novel RNA therapies. The company utilizes a sophisticated AI platform designed to untangle the complexities of biological data, allowing for the identification of therapeutic targets that were previously considered undruggable. By leveraging automation and deep learning, the firm aims to revolutionize the drug development lifecycle, reducing the time and cost associated with bringing genetic treatments to market. Their market position is defined by a commitment to precision medicine, where treatments are tailored to the specific genetic causes of disease, positioning them as a critical player in the future of genomic medicine.
How much funding has Deep Genomics raised?
Deep Genomics has raised a total of $196.7M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$13M
Series C
$180M
Angel/Seed (2015): $3.8M with participation from Bloomberg and True Ventures
Series A (2017): $13M led by True Ventures and Khosla Ventures
Series C (2021): $180M supported by CPP Investments, Fidelity Management & Research Company LLC, and SoftBank Vision Fund 2
Key Investors in Deep Genomics
True Ventures
True Ventures is a founder-first venture capital firm that partners with creative teams at the earliest stages, providing capital, guidance, and a strong community to help build enduring technology and artificial intelligence-driven companies.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, with a focus on AI, health, and sustainable energy.
CPP Investments
Canada Pension Plan Investment Board is a professional investment management organization that manages the fund in the best interest of the Canada Pension Plan contributors and beneficiaries.
What's next for Deep Genomics?
With the recent influx of capital, Deep Genomics is well-positioned to transition its lead candidates into clinical development. The strategic focus will likely shift toward expanding its internal R&D capabilities and strengthening its intellectual property portfolio in RNA biology. As the company matures, the emphasis will remain on validating its AI-driven discovery engine through successful clinical outcomes and potential partnerships with larger pharmaceutical entities. The firm's ability to maintain its technological edge while navigating the regulatory landscape will be the primary determinant of its long-term success in the competitive biotech landscape.
See full Deep Genomics company page
